文献速递白血病造血干细胞移植与细胞治疗

50岁以上急性髓系白血病缓解期患者中年轻MUD与年长MRD在移植后环磷酰胺方案下的比较

Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
PubMed 文献 · Leukemia · 2024-07-24

该研究比较了50岁以上首次完全缓解的急性髓系白血病患者接受年轻10/10相合无关供者(MUD)与年长相合亲缘供者(MRD)移植的结局,所有患者均使用移植后环磷酰胺(PTCy)。共纳入345例连续患者并按移植预处理强度(TCI)评分分层。多变量分析显示,在TCI中/高强度组中,MUD与更好的无移植物抗宿主病无复发生存率、更低的非复发死亡率和更低的复发率相关;在TCI低强度组中,结局与供者类型无关。

要点

  • 在TCI中/高强度组,年轻MUD较年长MRD有更优的无GVHD无复发生存、更低NRM和复发。
  • 在TCI低强度组,供者类型对结局无显著影响。
  • 对于50岁以上CR1期AML患者,使用PTCy且接受TCI中/高强度预处理时,年轻MUD优于年长MRD。

核心结论

  • 在50岁以上首次完全缓解的AML患者中,使用PTCy且接受TCI中/高强度预处理时,年龄小于40岁的MUD优于年龄大于50岁的MRD。

研究设计与样本

  • 比较性队列研究,纳入345例连续患者,均为50岁以上首次完全缓解的AML患者,接受首次异基因造血干细胞移植,供者类型为年龄小于40岁的10/10相合无关供者(MUD)或年龄大于50岁的相合亲缘供者(MRD),所有患者均使用移植后环磷酰胺(PTCy),并按已知的移植预处理强度(TCI)评分分为低、中、高组。

主要发现

  • 在TCI中/高强度组的多变量分析中,MUD与更好的无移植物抗宿主病无复发生存率相关,与更低的非复发死亡率和更低的复发发生率相关。
  • 对于接受TCI低强度方案的患者,结局与供者类型无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An increasing number of older patients with acute myeloid leukemia (AML) are offered an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients have older matched related donors (MRD). Matched unrelated donors (MUD) are an important alternative, but it remains unclear whether a younger MUD is associated with better outcomes, especially in the context of post-transplant cyclophosphamide (PTCy). We compared outcomes of patients older than 50 years with AML in first complete remission (CR1) and receiving a first HSCT from a 10/10 MUD aged younger than 40 years to those receiving a graft from a MRD aged older than 50 years, using PTCy and with well-known transplant conditioning intensity (TCI) score. A total of 345 consecutive patients were included and classified according to TCI score as low, intermediate, or high. On multivariable analysis in the TCI-intermediate/high group, MUD was associated with better graft-versus-host disease-free, relapse-free survival, lower non-relapse mortality and lower relapse incidence. For patients receiving a TCI-low regimen, outcomes are independent on the type of donor. In patients with AML in CR1, older than 50 years and receiving a TCI-intermediate/high conditioning regimen using PTCy, a MUD younger than 40 years is preferable over a MRD older than 50 years.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Piemontese S, Labopin M, Choi G, et al. Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. Leukemia. 2024. PMID: 39048722. doi:10.1038/s41375-024-02359-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。